On or around 09/26/2017 (Court's order of dismissal)
Filing Date: March 14, 2017
According to the law firm press release, Argos’ product candidate AGS-003 (rocapuldencel-T) is being evaluated in a pivotal ADAPT Phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). The complaint alleges that Argos issued materially false and/or misleading statements, causing the stock to trade at artificially inflated prices; following the release of adverse information, shares of Argos plummeted, damaging investors. In particular, the complaint alleges that Argos issued materially false and/or misleading information regarding the success and potential of its drug candidate AGS-003 (rocapuldencel-T).
On February 22, 2017, despite positive statements made by the Company, Argos then announced that the ADAPT study would be discontinued for futility. Following this news, shares of Argos fell approximately 66% to close at $1.48 per share on February 22, 2017.
On June 23, 2017, the Court appointed Co-Lead Plaintiffs and Lead Counsel.
On September 19, 2017, the parties filed a Stipulation expressing their intent to voluntarily dismiss this action. Pursuant to the Stipulation, the Court ordered this case dismissed on September 26.
Company & Securities Information
Defendant: Argos Therapeutics, Inc.
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: ARGS
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Jeffrey Maurer, et al. v. Argos Therapeutics, Inc., et al.
COURT: M.D. North Carolina
DOCKET #: 17-CV-00216
JUDGE: Hon. THOMAS D. SCHROEDER
DATE FILED: 03/14/2017
CLASS PERIOD START: 02/07/2014
CLASS PERIOD END: 02/21/2017
PLAINTIFF FIRMS NAMED IN COMPLAINT:
Levi & Korsinsky (Stamford) 733 Summer Street, Suite 304, Levi & Korsinsky (Stamford), CT 06901 203-992-4523 ·
Ward Black Law 208 W. Wendover Avenue, Ward Black Law, NC 27401 336.333.2244 336.379.9415 ·
First Identified Complaint (FIC) Filings:
Complaint for Violation of the Federal Securities Laws
Order Appointing Co-Lead Plaintiffs and Approving Selection of Co-Lead Counsel
Joint Stipulation and [Proposed] Order of Dismissal without Prejudice
U.S. District Court Civil Docket
Order of Dismissal without Prejudice
—Reference Complaint Complaint Related Data is not available
Related District Court Filings
—Related District Court Filings Data is not available